UroGen Pharma (URGN) Net Equity Issued and Repurchased (2017 - 2025)

UroGen Pharma (URGN) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $31.8 million the latest figure, recorded in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $31.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 57.9% YoY) and the FY2025 annual result came in at $39.8 million, down 73.67% from the prior year.
• Net Equity Issued and Repurchased grew to $31.8 million in Q4 2025 per URGN's latest filing, from $8.2 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for URGN reached as high as $80.1 million in Q2 2024 and fell as low as -$4000.0 in Q2 2025.
• A 3-year average of $32.3 million and a median of $23.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The largest YoY upside for Net Equity Issued and Repurchased was 45.34% in 2025 against a maximum downside of 100.0% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at $67.4 million in 2023, then sank by 77.73% to $15.0 million in 2024, then surged by 112.16% to $31.8 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $31.8 million, $8.2 million, and -$4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.